When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AZRX - AzurRx up 30% on start of mid-stage study of MS1819-SD
AzurRx BioPharma Inc.
Dosing is underway in a Phase 2 clinical trial, OPTION, evaluating AzurRx BioPharma's (AZRX+30%) MS1819-SD in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency, a deficiency in pancreatic enzymes that prevents normal food digestion.
More news on: AzurRX Biopharma, Healthcare stocks news, Stocks on the move,